Търсене на изпитвания

Намерени 4,436 изпитвания Стр. 186 от 222

Набира участници Фаза 2

MTX-001 for the Treatment of Non-Healing Venous Stasis Ulcers

Venous Stasis Ulcer Venous Leg Ulcer

DL-VSU-201 is a randomized, double-blind, placebo-controlled study in subjects with a non-infected venous stasis ulcer (VSU) that has failed to demonstrate improvement after receiving at least 4 weeks of standard, conventional wound therapy to evaluate the efficacy and safety of MTX-001.

Начало: 26.02.2022 Край: 31.05.2027 Възраст: от 18 г.

United States Merakris Therapeutics NCT04647240

Набира участници

The Australian HCV Point-of-Care Testing Program

Hepatitis C

The National Australian HCV Point-of-Care Testing Program will establish an observational cohort to evaluate whether scale-up of finger-stick point-of-care HCV testing increases diagnosis and treatment for HCV infection. Participants will be recruited from settings providing services to people with a risk factor for the acquisition of HCV infection (including drug treatment clinics, needle and syringe programs, homelessness settings, mental health services, prisons, and mobile outreach). Participants will attend a single visit to have their HCV RNA status tested and complete a self-administered survey. Participants will not receive treatment as a part of this study. Participants who are HCV RNA positive will be linked to standard of care.

Начало: 22.02.2022 Край: 30.06.2029 Възраст: от 18 г.

Australia Kirby Institute NCT05042544

Набира участници Фаза 3

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

Non-Small Cell Lung Cancer

This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with locally advanced (Stage III), unresectable NSCLC whose disease has not progressed following definitive platinum-based cCRT.

Начало: 18.02.2022 Край: 01.10.2030 Възраст: от 18 г.

Belgium, Brazil, Canada +25 AstraZeneca NCT05211895

Набира участници Фаза 1/2

Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant

Prevention of Rejection in Kidney Transplant

This study will evaluate the safety, PK, and efficacy of AT 1501 in patients undergoing kidney transplantation.

Начало: 18.02.2022 Край: 01.01.2027 Възраст: 18–100 г. Лечение

Australia, Brazil, Canada +2 Eledon Pharmaceuticals NCT05027906

Набира участници Фаза 2

Improving Early Reperfusion With Adjuvant Dornase Alfa in Large Vessel Ischemic Stroke (EXTEND-IA DNase)

Ischemic Stroke

Patients presenting to the emergency department with acute ischemic stroke, who are are eligible for standard intravenous thrombolytic therapy within 4.5 hours of stroke onset will be assessed for major vessel occlusion to determine their eligibility for the trial. All participants will receive intravenous tenecteplase (or alteplase due to manufacturer shortage) and endovascular thrombectomy as standard care. The trial is a Bayesian Optimised Phase 2 dose-finding umbrella trial (single arm versus objective performance criterion of 20% substantial reperfusion prior to endovascular thrombectomy based on the EXTEND-IA TNK trials NCT02388061, NCT03340493). The aim is to determine the optimal dose of intravenous dornase alfa (recombinant human DNase 1) with sufficient promise to take forward in a seamless phase 2b/3 design.

Начало: 18.02.2022 Край: 31.12.2025 Възраст: от 18 г. Лечение

Australia University of Melbourne NCT05203224

Набира участници

Real World Assessment of People Living With Chronic Hepatitis B in Australia

Hepatitis B

The REACH-B study establishes an observational cohort study of people living with chronic hepatitis B from a national network, including a diverse range of services, to characterise and monitor hepatitis B linkage to care and treatment requirements amongst this population.

Начало: 17.02.2022 Край: 01.07.2027 Възраст: от 18 г.

Australia Kirby Institute NCT04914611

Набира участници Фаза 2

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the study will be conducted in subjects whose tumors are Cyclin E1 positive as determined by central review using the Sponsor's investigational clinical trial assay.

Начало: 17.02.2022 Край: 30.06.2027 Възраст: от 18 г. Лечение

Australia, Belgium, France +5 K-Group, Beta, Inc., a wholly owned subsidiary of Zenta NCT05128825

Набира участници Фаза 4

Staphylococcus Aureus Network Adaptive Platform Trial

Staphylococcus Aureus Bacteremia

The Staphylococcus aureus Network Adaptive Platform (SNAP) trial is an International Multi-Centered Randomised Adaptive Platform Clinical Trial to evaluate a range of interventions to reduce mortality for patients with Staphylococcus Aureus bacteraemia (SAB).

Начало: 16.02.2022 Край: 01.12.2028 Лечение

Australia, Canada, Israel +7 University of Melbourne NCT05137119

Набира участници

Study to Evaluate the Safety and Effectiveness of the REAL INTELLIGENCE™ CORI™ in Total Knee Arthroplasty (TKA) Procedure

Arthroplasty Replacement Knee

Background: REAL INTELLIGENCE™ CORI™ (CORI Robotics) is a computer-assisted orthopaedic surgical navigation and burring system. CORI Robotics is designed to help surgeons in planning and executing certain types of knee surgery involving bone preparation. These types of surgery are called 'unicondylar knee arthroplasty' (UKA) and 'total knee arthroplasty' (TKA). Purpose: This study is being carried out to demonstrate the safety and effectiveness of the CORI Robotics in TKA procedure. The data collected will be used to demonstrate the safety and effectiveness of CORI and to register CORI in China mainland. The primary objective of this study is to evaluate the use of CORI in TKA procedure in achieving post-operative leg alignment as compared to procedures using conventional manual instruments. Research participants / locations: 140 research participants will be recruited from up to 8 sites in 3 countries globally (Australia, China Mainland, Hong Kong and New Zealand). There will be 70 patients having TKA using CORI and 70 patients having TKA using conventional procedure.

Начало: 12.02.2022 Край: 31.03.2028 Възраст: от 18 г. Лечение

Australia, China, Hong Kong +1 Smith & Nephew, Inc. NCT04848896

Набира участници Фаза 1/2

Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

Solid Tumor Advanced Solid Tumor

This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of IMP9064 as monotherapy or in combination with PARP inhibitor Senaparib in patients with advanced solid tumors

Начало: 11.02.2022 Край: 31.12.2026 Възраст: от 18 г. Лечение

Australia, China, Taiwan +1 Impact Therapeutics, Inc. NCT05269316

Набира участници Фаза 3

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

Crohn's Disease (CD)

Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, children and teenagers with moderate to severe Crohn's disease will be treated with vedolizumab. The main aim of the study is to check if participants achieve remission after treatment with the vedolizumab. Remission means symptoms improve or disappear and an endoscopy shows no signs of inflammation. Participants will receive 3 infusions of vedolizumab over 6 weeks. Then, those who have a clinical response will receive either a high dose or low dose of vedolizumab once every 8 weeks. They will receive the same dose every time.

Начало: 10.02.2022 Край: 22.05.2026 Възраст: 2–17 г. Лечение

Australia, Belgium, Canada +15 Takeda NCT04779320

Набира участници Фаза 2

NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma

Renal Cell Carcinoma, Clear Cell, Somatic

This is a prospective, open label, phase II, randomised, non-comparative clinical trial, evaluating changes in tumour-responsive T-cells following neoadjuvant stereotactic ablative body radiotherapy (SABR) with or without pembrolizumab, prior to nephrectomy, in patients with localised primary clear cell renal cell carcinoma (ccRCC).

Начало: 08.02.2022 Край: 01.12.2025 Възраст: от 18 г. Лечение

Australia Peter MacCallum Cancer Centre, Australia NCT05024318

Набира участници Фаза 1/2

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Acute Biphenotypic Leukemia Acute Myeloid Leukemia Mixed Phenotype Acute Leukemia Myeloid Neoplasm +9

This phase I/II trial finds the best dose, side effects and how well giving venetoclax in combination with cladribine, cytarabine, granulocyte colony-stimulating factor, and mitoxantrone (CLAG-M) in treating patients with acute myeloid leukemia and high-grade myeloid neoplasms. Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Chemotherapy drugs, such as cladribine, cytarabine, and mitoxantrone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax with CLAG-M may kill more cancer cells.

Начало: 04.02.2022 Край: 31.12.2028 Възраст: от 18 г.

United States University of Washington NCT04797767

Набира участници Фаза 2

Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

Primary Immune Thrombocytopenia

This is a Phase 2, open-label, multicenter, multiple subcutaneous injection, safety and efficacy study of PF-06835375 in adult participants with primary immune thrombocytopenia (ITP). This study will focus on participants with persistent (\>3 months and ≤12 months), or chronic (\>12 months) ITP

Начало: 02.02.2022 Край: 02.08.2028 Възраст: 18–70 г. Лечение

Australia, Canada, Czechia +4 Pfizer NCT05070845

Набира участници

Real-time Symptom Monitoring Using ePROs to Prevent Adverse Events During Care Transitions

Multiple Chronic Conditions Adverse Event

This study aims to predict and minimize post-discharge adverse events (AEs) during care transitions through early identification and escalation of patient-reported symptoms to inpatient and ambulatory clinicians by way of predictive algorithms and clinically integrated digital health apps. We will (1) develop and prospectively validate a predictive model of post-discharge AEs for patients with multiple chronic conditions (MCC); (2) combine, adapt, extend, and iteratively refine our EHR-integrated digital health infrastructure in a series of design sessions with patient and clinician participants; (3) conduct a RCT to evaluate the impact of ePRO monitoring on post-discharge AEs for MCC patients discharged from the general medicine service across Brigham Health; and (4) use mixed methods to evaluate barriers and facilitators of implementation and use as we develop a plan for sustainability, scale, and dissemination.

Начало: 01.02.2022 Край: 15.10.2026 Възраст: от 18 г.

United States Brigham and Women's Hospital NCT05282654

Набира участници

Visual Remapping to Aid Reading With Field Loss

Age-related Macular Degeneration

Reading performance in patients with Central Vision Loss and age matched controls with artificial scotomas will be measured with and without different kinds of remapping of missing text to different parts of the visual field.

Начало: 01.02.2022 Край: 01.07.2026 Възраст: от 16 г.

United States University of Minnesota NCT03848663

Набира участници

Correlation Between Intestinal Microecology Imbalance and Stroke in Young Adults

Ischemic Stroke Hemorrhagic Stroke

The relationship between the intestinal microecology and stroke has become a research hotspot in neurology field today. Maintaining the balance of the intestinal microbiota are expected to bring new breakthroughs for prevention and treatment of stroke. In recent years, stroke in young adults has an increasing incidence and a considerable socioeconomic impact because of high disability rate and health-care costs. So there is an urgent need to explore the role and mechanism of intestinal microecology imbalance in stroke, especially in the development and prognosis of stroke in young people. This study aims to use multi-omics technologies, including microbial diversity, metagenomics and metabonomics, to reveal the characteristics of intestinal flora in young stroke patients, identify biomarkers for predicting outcome after stroke and early detection of young people at high risk of stroke, and to further explore the role of gut-brain axis in the pathogenesis of stroke.

Начало: 01.02.2022 Край: 31.12.2027 Възраст: 18–45 г.

China Shanghai 6th People's Hospital NCT05113043

Набира участници

Timing of Necrosectomy After Endoscopic Drainage of Walled-off Pancreatic Necrosis (WON)

Pancreatic Necrosis

Walled-off pancreatic necrosis (WON) is associated with a mortality of 20-30%. The current evidence supports a minimally invasive drainage approach to infected WON. The current suggested approach in international guidelines is the endoscopic step-up approach. However, recent evidence from large national cohorts support the use of direct endoscopic necrosectomy (DEN) at the time of stent placement, resulting in earlier resolution of WON and less number of necrosectomies. This study aims to investigate the clinical outcomes of the DEN versus the step-up approach for necrosectomy after endoscopic drainage of WON.

Начало: 01.02.2022 Край: 30.06.2026 Възраст: от 18 г. Лечение

Australia, Hong Kong, India +3 Chinese University of Hong Kong NCT05252897

Набира участници

Improving Socket Fit in Female and Male Veterans With Transtibial and Transfemoral Amputation

Transtibial Amputation Transfemoral Amputation

The investigators do not yet know how a prosthetic socket with adjustable panels affects the performance of people with a lower limb amputation compared to a conventional prosthetic socket. The primary objective of this study is to compare an adjustable and conventional prosthetic socket and use this information to determine the optimal socket that would improve rehabilitation and function in people with lower limb amputation.

Начало: 31.01.2022 Край: 31.03.2027 Възраст: 18–65 г.

United States VA Office of Research and Development NCT05989243

Набира участници

Predictors of Poor Prognosis in HFpEF

HFpEF

Patients with HFpEF who have undergone meticulous clinical and instrumental evaluation (including diastolic exercise testing) between 2013 and 2020, will be followed up for at least 3 years.

Начало: 31.01.2022 Край: 31.12.2026 Възраст: от 40 г.

Russia National Medical Research Center for Cardiology, Minist NCT06844032

1 … 184 185 186 187 188 … 222